These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 32837681)

  • 1. A history of the roles of cytochrome P450 enzymes in the toxicity of drugs.
    Guengerich FP
    Toxicol Res; 2021 Jan; 37(1):1-23. PubMed ID: 32837681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Roles of cytochrome P450 enzymes in pharmacology and toxicology: Past, present, and future.
    Guengerich FP
    Adv Pharmacol; 2022; 95():1-47. PubMed ID: 35953152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A passion for P450s (rememberances of the early history of research on cytochrome P450).
    Estabrook RW
    Drug Metab Dispos; 2003 Dec; 31(12):1461-73. PubMed ID: 14625342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Roles of Individual Human Cytochrome P450 Enzymes in Drug Metabolism.
    Guengerich FP
    Pharmacol Rev; 2024 Oct; 76(6):1104-1132. PubMed ID: 39054072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytochrome P450s and other enzymes in drug metabolism and toxicity.
    Guengerich FP
    AAPS J; 2006 Mar; 8(1):E101-11. PubMed ID: 16584116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome p450 and chemical toxicology.
    Guengerich FP
    Chem Res Toxicol; 2008 Jan; 21(1):70-83. PubMed ID: 18052394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of Cytochrome P450 Enzymes by Drugs-Molecular Basis and Practical Applications.
    Guengerich FP
    Biomol Ther (Seoul); 2022 Jan; 30(1):1-18. PubMed ID: 34475272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cytochrome P450 enzymes in drug-drug interactions.
    Guengerich FP
    Adv Pharmacol; 1997; 43():7-35. PubMed ID: 9342171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism-based inactivation of human cytochromes p450s: experimental characterization, reactive intermediates, and clinical implications.
    Hollenberg PF; Kent UM; Bumpus NN
    Chem Res Toxicol; 2008 Jan; 21(1):189-205. PubMed ID: 18052110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition and induction of cytochrome P450 and the clinical implications.
    Lin JH; Lu AY
    Clin Pharmacokinet; 1998 Nov; 35(5):361-90. PubMed ID: 9839089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions.
    Rooney PH; Telfer C; McFadyen MC; Melvin WT; Murray GI
    Curr Cancer Drug Targets; 2004 May; 4(3):257-65. PubMed ID: 15134533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450: what have we learned and what are the future issues?
    Guengerich FP
    Drug Metab Rev; 2004 May; 36(2):159-97. PubMed ID: 15237850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450. Mechanisms of action and clinical implications.
    Williams MT
    J Fla Med Assoc; 1992 Jun; 79(6):405-8. PubMed ID: 1640215
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Metabolism: A Half-Century Plus of Progress, Continued Needs, and New Opportunities.
    Guengerich FP
    Drug Metab Dispos; 2023 Jan; 51(1):99-104. PubMed ID: 35868640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel cytochrome P450 mono-oxygenase from Streptomyces platensis resembles activities of human drug metabolizing P450s.
    Worsch A; Eggimann FK; Girhard M; von Bühler CJ; Tieves F; Czaja R; Vogel A; Grumaz C; Sohn K; Lütz S; Kittelmann M; Urlacher VB
    Biotechnol Bioeng; 2018 Sep; 115(9):2156-2166. PubMed ID: 29943426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reaction Phenotyping of Low-Turnover Compounds in Long-Term Hepatocyte Cultures Through Persistent Selective Inhibition of Cytochromes P450.
    Smith S; Lyman M; Ma B; Tweedie D; Menzel K
    Drug Metab Dispos; 2021 Nov; 49(11):995-1002. PubMed ID: 34407991
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of cytochrome P450 reactivity on the characterization of chemical compounds and its association with repeated-dose toxicity.
    Watanabe M; Sasaki T; Takeshita JI; Kushida M; Shimizu Y; Oki H; Kitsunai Y; Nakayama H; Saruhashi H; Ogura R; Shizu R; Hosaka T; Yoshinari K
    Toxicol Appl Pharmacol; 2020 Feb; 388():114854. PubMed ID: 31836524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Designing better drugs: predicting cytochrome P450 metabolism.
    de Groot MJ
    Drug Discov Today; 2006 Jul; 11(13-14):601-6. PubMed ID: 16793528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanism-based inactivation of cytochrome P450 enzymes: chemical mechanisms, structure-activity relationships and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions.
    Kalgutkar AS; Obach RS; Maurer TS
    Curr Drug Metab; 2007 Jun; 8(5):407-47. PubMed ID: 17584015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro inhibitory mechanisms and molecular docking of 1'-S-1'-acetoxychavicol acetate on human cytochrome P450 enzymes.
    Haque AKMM; Leong KH; Lo YL; Awang K; Nagoor NH
    Phytomedicine; 2017 Jul; 31():1-9. PubMed ID: 28606510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.